Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence Imaging

Martine L M Lamfers, Giulia Fulci, Davide Gianni, Yi Tang, Kazuhiko Kurozumi, Balveen Kaur, Sharif Moeniralm, Yoshinaga Saeki, Jan E. Carette, Ralph Weissleder, W. Peter Vandertop, Victor W. van Beusechem, Clemens M F Dirven, E. Antonio Chiocca

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Approaches to improve the oncolytic potency of replication-competent adenoviruses include the insertion of therapeutic transgenes into the viral genome. Little is known about the levels and duration of in vivo transgene expression by cells infected with such "armed" viruses. Using a tumor-selective adenovirus encoding firefly luciferase (AdΔ24CMV-Luc) we investigated these questions in an intracranial mouse model for malignant glioma. Luciferase expression was detected by bioluminescence imaging, and the effect of the immunosuppressive agent cyclophosphamide (CPA) on transgene expression was assessed. Intratumoral AdΔ24CMV-Luc injection led to a localized dose-dependent expression of luciferase. Surprisingly, this expression decreased rapidly during the course of 14 days. In contrast, mice injected with nonreplicating Ad.CMV-Luc demonstrated stable transgene expression. Treatment of mice with CPA in combination with AdΔ24CMV-Luc retarded the loss of transgene expression. Staining of mouse brains for inflammatory cells demonstrated decreased tumor infiltration by immune cells in CPA-treated mice. Moreover, in immunodeficient NOD/SCID mice loss of transgene expression was less rapid and not prevented by CPA treatment. Together, our data demonstrate that transgene expression and viral replication decrease rapidly after intratumoral injection of oncolytic adenovirus in mouse brains and that treatment with the immunomodulator CPA prolongs viral-mediated gene expression.

Original languageEnglish
Pages (from-to)779-788
Number of pages10
JournalMolecular Therapy
Volume14
Issue number6
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Fingerprint

Transgenes
Adenoviridae
Glioma
Cyclophosphamide
Luciferases
Firefly Luciferases
Inbred NOD Mouse
Injections
SCID Mice
Viral Genes
Viral Genome
Brain
Immunologic Factors
Therapeutics
Immunosuppressive Agents
Neoplasms
Staining and Labeling
Viruses
Gene Expression

Keywords

  • bioluminescence imaging
  • glioma
  • immune suppression
  • oncolytic adenovirus
  • transgene expression

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence Imaging. / Lamfers, Martine L M; Fulci, Giulia; Gianni, Davide; Tang, Yi; Kurozumi, Kazuhiko; Kaur, Balveen; Moeniralm, Sharif; Saeki, Yoshinaga; Carette, Jan E.; Weissleder, Ralph; Vandertop, W. Peter; van Beusechem, Victor W.; Dirven, Clemens M F; Chiocca, E. Antonio.

In: Molecular Therapy, Vol. 14, No. 6, 12.2006, p. 779-788.

Research output: Contribution to journalArticle

Lamfers, MLM, Fulci, G, Gianni, D, Tang, Y, Kurozumi, K, Kaur, B, Moeniralm, S, Saeki, Y, Carette, JE, Weissleder, R, Vandertop, WP, van Beusechem, VW, Dirven, CMF & Chiocca, EA 2006, 'Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence Imaging', Molecular Therapy, vol. 14, no. 6, pp. 779-788. https://doi.org/10.1016/j.ymthe.2006.08.008
Lamfers, Martine L M ; Fulci, Giulia ; Gianni, Davide ; Tang, Yi ; Kurozumi, Kazuhiko ; Kaur, Balveen ; Moeniralm, Sharif ; Saeki, Yoshinaga ; Carette, Jan E. ; Weissleder, Ralph ; Vandertop, W. Peter ; van Beusechem, Victor W. ; Dirven, Clemens M F ; Chiocca, E. Antonio. / Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence Imaging. In: Molecular Therapy. 2006 ; Vol. 14, No. 6. pp. 779-788.
@article{b95a852f7132499fa3d797a19f691356,
title = "Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence Imaging",
abstract = "Approaches to improve the oncolytic potency of replication-competent adenoviruses include the insertion of therapeutic transgenes into the viral genome. Little is known about the levels and duration of in vivo transgene expression by cells infected with such {"}armed{"} viruses. Using a tumor-selective adenovirus encoding firefly luciferase (AdΔ24CMV-Luc) we investigated these questions in an intracranial mouse model for malignant glioma. Luciferase expression was detected by bioluminescence imaging, and the effect of the immunosuppressive agent cyclophosphamide (CPA) on transgene expression was assessed. Intratumoral AdΔ24CMV-Luc injection led to a localized dose-dependent expression of luciferase. Surprisingly, this expression decreased rapidly during the course of 14 days. In contrast, mice injected with nonreplicating Ad.CMV-Luc demonstrated stable transgene expression. Treatment of mice with CPA in combination with AdΔ24CMV-Luc retarded the loss of transgene expression. Staining of mouse brains for inflammatory cells demonstrated decreased tumor infiltration by immune cells in CPA-treated mice. Moreover, in immunodeficient NOD/SCID mice loss of transgene expression was less rapid and not prevented by CPA treatment. Together, our data demonstrate that transgene expression and viral replication decrease rapidly after intratumoral injection of oncolytic adenovirus in mouse brains and that treatment with the immunomodulator CPA prolongs viral-mediated gene expression.",
keywords = "bioluminescence imaging, glioma, immune suppression, oncolytic adenovirus, transgene expression",
author = "Lamfers, {Martine L M} and Giulia Fulci and Davide Gianni and Yi Tang and Kazuhiko Kurozumi and Balveen Kaur and Sharif Moeniralm and Yoshinaga Saeki and Carette, {Jan E.} and Ralph Weissleder and Vandertop, {W. Peter} and {van Beusechem}, {Victor W.} and Dirven, {Clemens M F} and Chiocca, {E. Antonio}",
year = "2006",
month = "12",
doi = "10.1016/j.ymthe.2006.08.008",
language = "English",
volume = "14",
pages = "779--788",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence Imaging

AU - Lamfers, Martine L M

AU - Fulci, Giulia

AU - Gianni, Davide

AU - Tang, Yi

AU - Kurozumi, Kazuhiko

AU - Kaur, Balveen

AU - Moeniralm, Sharif

AU - Saeki, Yoshinaga

AU - Carette, Jan E.

AU - Weissleder, Ralph

AU - Vandertop, W. Peter

AU - van Beusechem, Victor W.

AU - Dirven, Clemens M F

AU - Chiocca, E. Antonio

PY - 2006/12

Y1 - 2006/12

N2 - Approaches to improve the oncolytic potency of replication-competent adenoviruses include the insertion of therapeutic transgenes into the viral genome. Little is known about the levels and duration of in vivo transgene expression by cells infected with such "armed" viruses. Using a tumor-selective adenovirus encoding firefly luciferase (AdΔ24CMV-Luc) we investigated these questions in an intracranial mouse model for malignant glioma. Luciferase expression was detected by bioluminescence imaging, and the effect of the immunosuppressive agent cyclophosphamide (CPA) on transgene expression was assessed. Intratumoral AdΔ24CMV-Luc injection led to a localized dose-dependent expression of luciferase. Surprisingly, this expression decreased rapidly during the course of 14 days. In contrast, mice injected with nonreplicating Ad.CMV-Luc demonstrated stable transgene expression. Treatment of mice with CPA in combination with AdΔ24CMV-Luc retarded the loss of transgene expression. Staining of mouse brains for inflammatory cells demonstrated decreased tumor infiltration by immune cells in CPA-treated mice. Moreover, in immunodeficient NOD/SCID mice loss of transgene expression was less rapid and not prevented by CPA treatment. Together, our data demonstrate that transgene expression and viral replication decrease rapidly after intratumoral injection of oncolytic adenovirus in mouse brains and that treatment with the immunomodulator CPA prolongs viral-mediated gene expression.

AB - Approaches to improve the oncolytic potency of replication-competent adenoviruses include the insertion of therapeutic transgenes into the viral genome. Little is known about the levels and duration of in vivo transgene expression by cells infected with such "armed" viruses. Using a tumor-selective adenovirus encoding firefly luciferase (AdΔ24CMV-Luc) we investigated these questions in an intracranial mouse model for malignant glioma. Luciferase expression was detected by bioluminescence imaging, and the effect of the immunosuppressive agent cyclophosphamide (CPA) on transgene expression was assessed. Intratumoral AdΔ24CMV-Luc injection led to a localized dose-dependent expression of luciferase. Surprisingly, this expression decreased rapidly during the course of 14 days. In contrast, mice injected with nonreplicating Ad.CMV-Luc demonstrated stable transgene expression. Treatment of mice with CPA in combination with AdΔ24CMV-Luc retarded the loss of transgene expression. Staining of mouse brains for inflammatory cells demonstrated decreased tumor infiltration by immune cells in CPA-treated mice. Moreover, in immunodeficient NOD/SCID mice loss of transgene expression was less rapid and not prevented by CPA treatment. Together, our data demonstrate that transgene expression and viral replication decrease rapidly after intratumoral injection of oncolytic adenovirus in mouse brains and that treatment with the immunomodulator CPA prolongs viral-mediated gene expression.

KW - bioluminescence imaging

KW - glioma

KW - immune suppression

KW - oncolytic adenovirus

KW - transgene expression

UR - http://www.scopus.com/inward/record.url?scp=33751005823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751005823&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2006.08.008

DO - 10.1016/j.ymthe.2006.08.008

M3 - Article

VL - 14

SP - 779

EP - 788

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -